Bharat Biotech to make variant-specific shots of first nasal Covid-19 vaccine https://ift.tt/bkSgsOx

With iNCOVACC becoming the world's first intranasal Covid-19 vaccine to receive emergency use authorisation (EUA) as a primary vaccine as well as a heterologous booster for those aged 18 years and above, Bharat Biotech is now working on developing variant-specific versions of the vaccine.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/BZUhomN
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.